Welcome - Debiopharm, We develop for patients Home Contact Center Add this About us Welcome At a glance Mission Values History Let's meet Debiopharm Group Debiopharm International S.A. Debiopharm Research Manufacturing S.A. Debiopharm Investment S.A. Debiopharm Diagnostics S.A. GenePOC Inc. Scientific Awards Grants Debiopharm Academy Entrepreneurship Social Responsibility Contact Center Our Headquarter is located in Lausanne/Switzerland.Phone +41 (0)21 321 0111 To find the numbers of all the Debiopharm Group's companies, use this page. Business Business Model Partnering Pipeline Translational Medicine Drug Discovery Preclinical Clinical development Innovative drug delivery and formulation Manufacturing Quality Assurance Regulatory Product Pipeline More info Products Eloxatin® / Elplat® / Dacotin® / Dacplat® Oxaliplatin is a diaminocyclohexane (DACH) platin for the treatment of colorectal cancer. Decapeptyl® / Trelstar® / Pamorelin® / Neo Decapeptyl® 1 to 6 month formulation for the treatment of prostate cancer, of endometriosis, precocious puberty, uterine fibroids, ovarian cancer, breast cancer, female infertility. Salvacyl® / Moapar® For the treatment of severe sexual deviations. We develop for patients More infos Careers Jobs Medical Director, Infectious DiseasesLausanne - 01 September 2016 Director, Head of PharmacovigilanceLausanne - 16 August 2016 Research Associate R D AnalytiqueMartigny - 03 August 2016 See all jobs SPONTANEOUS APPLICATION Working at Debiopharm Approximately 350 people of more than 18 nationalities - from Europe, North and South America, Africa and Asia - are employed at Debiopharm Group on its sites. More info Media Corporate Profile Press Releases Events Contact media relations Publications Logo Media Download Area Videos Latest news Debiopharm invests double digit millions in the Canadian startup GenePOC, specialized in the development of rapid diagnostic testsGenePOC Inc. - 30 August 2016 All News Debiopharm TV × Add this to your social network ! Let's meet ID Week 2016 October 26-30, 2016ALL EVENTS Follow ourProduct Pipeline Debiopharmin 90 seconds All News International Local Publications 30 August 2016 / international Debiopharm invests double digit millions in the Canadian startup GenePOC, specialized in the development of rapid diagnostic tests [Read more] 13 July 2016 / international Debiopharm acquires a majority holding in the Canadian start-up GenePOC [Read more] 11 July 2016 / international Grand succès du Challenge Debiopharm Inartis [Read more] ALL NEWS 02 June 2016 FDA grants Orphan Drug Designation to Debiopharm International SAs IAP inhibitor Debio 1143 in the treatment of ovarian cancer [Read more] 15 April 2016 Debiopharm International SA announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor [Read more] 08 April 2016 Debiopharm International SA to present the latest findings on Debio 1450 at ECCMID [Read more] ALL NEWS 18 December 2014 Debiopharm Investment, Ardian, Nixdorf Foundation and Bernis today acquire Eco Delta solar activities [Read more] 27 November 2014 Debiopharm Investment becomes a minority shareholder in Haut-Lac International Bilingual School in St-Légier (VD) [Read more] 17 November 2014 Coorpacademy, établi à lEPFL et lun des leaders des MOOCs à destination des entreprises, lève 3,2 millions deuros auprès de Debiopharm Investment et du fonds français NextStage [Read more] ALL NEWS 21 June 2016 Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients [Read more] 30 April 2016 Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Y. [Read more] 21 April 2016 FGFR selective inhibitor Debio1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models [Read more] ALL NEWS Debiopharm Group presented at a glance Follow our Product Pipeline DiscoverDebiopharm TV Social CorporateResponsibility © 2016 Debiopharm Group Legal Notice Terms Conditions CSOnline Credits Sitemap Previous Next